Review





Similar Products

next generation sequencing  (Illumina Inc)
96
Illumina Inc next generation sequencing
Next Generation Sequencing, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pm41653877-2-16-21?v=Illumina+Inc
Average 96 stars, based on 1 article reviews
next generation sequencing - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
trusight rna pan cancer next generation sequencing panel  (Illumina Inc)
96
Illumina Inc trusight rna pan cancer next generation sequencing panel
Trusight Rna Pan Cancer Next Generation Sequencing Panel, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pm40394848-14-6-5?v=Illumina+Inc
Average 96 stars, based on 1 article reviews
trusight rna pan cancer next generation sequencing panel - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
next generation sequencing ngs  (Sophia Genetics)
97
Sophia Genetics next generation sequencing ngs
Next Generation Sequencing Ngs, supplied by Sophia Genetics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pmc12347601-108-21-28?v=Sophia+Genetics
Average 97 stars, based on 1 article reviews
next generation sequencing ngs - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
next generation sequencing ngs  (Illumina Inc)
96
Illumina Inc next generation sequencing ngs
Next Generation Sequencing Ngs, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pmc12197955-229-0-17?v=Illumina+Inc
Average 96 stars, based on 1 article reviews
next generation sequencing ngs - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
targeted next-generation sequencing illumina cancer hotspot panel v2  (Illumina Inc)
90
Illumina Inc targeted next-generation sequencing illumina cancer hotspot panel v2
Targeted Next Generation Sequencing Illumina Cancer Hotspot Panel V2, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pm40066702-138-17-20?v=Illumina+Inc
Average 90 stars, based on 1 article reviews
targeted next-generation sequencing illumina cancer hotspot panel v2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
generation sequencing panel  (Sophia Genetics)
97
Sophia Genetics generation sequencing panel
Generation Sequencing Panel, supplied by Sophia Genetics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pm39774677-25-6-17?v=Sophia+Genetics
Average 97 stars, based on 1 article reviews
generation sequencing panel - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
next generation sequencing ngs sophia genetics  (Sophia Genetics)
97
Sophia Genetics next generation sequencing ngs sophia genetics
Next Generation Sequencing Ngs Sophia Genetics, supplied by Sophia Genetics, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pm39941313-64-8-11?v=Sophia+Genetics
Average 97 stars, based on 1 article reviews
next generation sequencing ngs sophia genetics - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier
next-generation sequencing (ngs) panel invitae common hereditary cancers panel  (Invitae Inc)
90
Invitae Inc next-generation sequencing (ngs) panel invitae common hereditary cancers panel
(A) Family tree with blue circles representing individuals affected with NF1. NF1 var: NF1 variant carrier. NF1 neg: NF1 variant screening negative. Arrow: proband. Crossed figures: deceased. (B) 18F-FDG PET/CT showing a pituitary lesion of with homogenous uptake of the contrast with a maximum standardized uptake value of 20.8. (C, D) sagittal and coronal gadolinium-enhanced MRI (T1), showing a 16x15x11 mm pituitary lesion on the left parasagittal aspect, contacting the wall of the cavernous sinus, with homogeneous enhancement and displacement of the pituitary stalk to the left and of the optic chiasm anteriorly. Arrowheads point to the lesion. (E) Timeline of patient evolution. TSS, transsphenoidal surgery; <t>NGS,</t> next generation <t>sequencing.</t>
Next Generation Sequencing (Ngs) Panel Invitae Common Hereditary Cancers Panel, supplied by Invitae Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/pmc11832379-111-16-20?v=Invitae+Inc
Average 90 stars, based on 1 article reviews
next-generation sequencing (ngs) panel invitae common hereditary cancers panel - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier
next generation panel sequencing ion ampliseqtm cancer hotspot panel v2  (Thermo Fisher)
90
Thermo Fisher next generation panel sequencing ion ampliseqtm cancer hotspot panel v2
(A) Family tree with blue circles representing individuals affected with NF1. NF1 var: NF1 variant carrier. NF1 neg: NF1 variant screening negative. Arrow: proband. Crossed figures: deceased. (B) 18F-FDG PET/CT showing a pituitary lesion of with homogenous uptake of the contrast with a maximum standardized uptake value of 20.8. (C, D) sagittal and coronal gadolinium-enhanced MRI (T1), showing a 16x15x11 mm pituitary lesion on the left parasagittal aspect, contacting the wall of the cavernous sinus, with homogeneous enhancement and displacement of the pituitary stalk to the left and of the optic chiasm anteriorly. Arrowheads point to the lesion. (E) Timeline of patient evolution. TSS, transsphenoidal surgery; <t>NGS,</t> next generation <t>sequencing.</t>
Next Generation Panel Sequencing Ion Ampliseqtm Cancer Hotspot Panel V2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/next-generation+cancer+sequencing/10__12659_slash_ajcr__946361-106-19-29?v=Thermo+Fisher
Average 90 stars, based on 1 article reviews
next generation panel sequencing ion ampliseqtm cancer hotspot panel v2 - by Bioz Stars, 2026-08
90/100 stars
  Buy from Supplier

Image Search Results


(A) Family tree with blue circles representing individuals affected with NF1. NF1 var: NF1 variant carrier. NF1 neg: NF1 variant screening negative. Arrow: proband. Crossed figures: deceased. (B) 18F-FDG PET/CT showing a pituitary lesion of with homogenous uptake of the contrast with a maximum standardized uptake value of 20.8. (C, D) sagittal and coronal gadolinium-enhanced MRI (T1), showing a 16x15x11 mm pituitary lesion on the left parasagittal aspect, contacting the wall of the cavernous sinus, with homogeneous enhancement and displacement of the pituitary stalk to the left and of the optic chiasm anteriorly. Arrowheads point to the lesion. (E) Timeline of patient evolution. TSS, transsphenoidal surgery; NGS, next generation sequencing.

Journal: Frontiers in Endocrinology

Article Title: Association of pituitary neuroendocrine tumors and neurofibromatosis type 1: assessing causation versus coincidence. Case report

doi: 10.3389/fendo.2025.1483305

Figure Lengend Snippet: (A) Family tree with blue circles representing individuals affected with NF1. NF1 var: NF1 variant carrier. NF1 neg: NF1 variant screening negative. Arrow: proband. Crossed figures: deceased. (B) 18F-FDG PET/CT showing a pituitary lesion of with homogenous uptake of the contrast with a maximum standardized uptake value of 20.8. (C, D) sagittal and coronal gadolinium-enhanced MRI (T1), showing a 16x15x11 mm pituitary lesion on the left parasagittal aspect, contacting the wall of the cavernous sinus, with homogeneous enhancement and displacement of the pituitary stalk to the left and of the optic chiasm anteriorly. Arrowheads point to the lesion. (E) Timeline of patient evolution. TSS, transsphenoidal surgery; NGS, next generation sequencing.

Article Snippet: A blood sample of the patient was first studied in a routine diagnostic laboratory via a next-generation sequencing (NGS) panel (Invitae Common Hereditary Cancers Panel).

Techniques: Variant Assay, Positron Emission Tomography-Computed Tomography, Next-Generation Sequencing